Log In
Print
BCIQ
Print
Print this Print this
 

Intermezzo, zolpidem

  Manage Alerts
Collapse Summary General Information
Company Paratek Pharmaceuticals Inc.
DescriptionLow-dose sublingual formulation of zolpidem
Molecular Target GABA A receptor
Mechanism of ActionGABA A receptor modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia; Treat insomnia when a middle of the night awakening is followed by difficulty returning to sleep
Regulatory Designation

Partner

Purdue Pharma L.P.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today